Somatic copy number variation as a prognostic marker for recurrence in never‐smokers with early‐stage lung adenocarcinoma
International Journal of Cancer · 01.06.2026 · 158 (11) · 2900-2911
DOI: 10.1002/ijc.70373 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 10.02.2026. Verfasst von Stijn Vanstraelen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: DNA Copy Number Variations, Lung Neoplasms, Neoplasm Recurrence, Local, Adenocarcinoma of Lung. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Lung cancer in never‐smokers has a distinct genomic profile characterized by lower tumor mutational burden, more tumor‐promoting mutations, and fewer somatic copy number variations (CNVs) compared to smokers. While CNVs are linked to poor outcomes in advanced‐stage cancer, their role in early‐stage lung adenocarcinoma remains unclear. In a cohort of 210 treatment‐naive never‐smokers with early‐stage lung adenocarcinoma, hierarchical clustering of CNVs identified three distinct groups: CNV low ( n = 86 [41%]), CNV moderate ( n = 75 [36%]), and CNV high ( n = 49 [23%]). CNV low tumors had minimal CNV burden, CNV moderate tumors exhibited loss of heterozygosity in chromosomes 3, 9, 13, 15, and 18, and CNV high tumors showed genome‐wide amplifications and whole‐genome doubling. Recurrence occurred in 42 patients (20%), with a significantly lower 5‐year cumulative incidence in the CNV low group (14% [95% CI, 7%–25%]) compared to the CNV moderate (31% [95% CI, 18%–44%]) and CNV high group (48% [95% CI, 27%–66%]) ( p = .004). Adjusted hazard ratios for recurrence were 2.30 ( p = .074) and 2.65 ( p = .037) for CNV moderate and CNV high, respectively. These findings suggest CNV status is an independent predictor of recurrence, with CNV low tumors being associated with the most favorable prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Gaetano Rocco
Förderung
- NCI NIH HHS
Zitieren
APA
Vanstraelen, S., Reiner, A., Tan, K. S., Mastrogiacomo, B., Dunne, E. G., Fick, C. N., Dycoco, J., Abass, A., Bott, M. J., Sanchez-Vega, F., Jones, D. R., & Rocco, G. (2026). Somatic copy number variation as a prognostic marker for recurrence in never‐smokers with early‐stage lung adenocarcinoma. International Journal of Cancer, 158(11), 2900-2911. https://doi.org/10.1002/ijc.70373
Vancouver
Vanstraelen S, Reiner A, Tan KS, Mastrogiacomo B, Dunne EG, Fick CN, et al. Somatic copy number variation as a prognostic marker for recurrence in never‐smokers with early‐stage lung adenocarcinoma. International Journal of Cancer. 2026;158(11):2900-2911. doi:10.1002/ijc.70373
BibTeX
@article{Vanstraelen2026,
author = {Vanstraelen, Stijn and Reiner, Allison and Tan, Kay See and Mastrogiacomo, Brooke and Dunne, Elizabeth G and Fick, Cameron N and Dycoco, Joseph and Abass, Aqib and Bott, Matthew J and Sanchez-Vega, Francisco and Jones, David R and Rocco, Gaetano},
title = {Somatic copy number variation as a prognostic marker for recurrence in never‐smokers with early‐stage lung adenocarcinoma},
journal = {International Journal of Cancer},
year = {2026},
volume = {158},
number = {11},
pages = {2900--2911},
doi = {10.1002/ijc.70373}
}
EUVIMED